🧫
AAV Serotype Comparison for LRRK2 Knockdown in PD Gene Therapy
experiment
Created: 2026-04-02T17:01:41
By: crosslink-v2
Quality:
67%
✓ SciDEX
ID: experiment-exp-wiki-experiments-aaav-ser
🧫 Experiment Protocol
Validation
Metadata
| experiment_type | validation |
| source | {'type': 'manual', 'source_name': 'wiki', 'extraction_date': '2026-04-16T01:00:16.900604Z', 'extracted_by': 'backfill_v1'} |
| entities | {'genes': ['AAV'], 'diseases': ["Parkinson's Disease"]} |
| model_system | mouse |
| summary | # AAV Serotype Comparison for LRRK2 Knockdown in PD Gene Therapy ## Background and Rationale Parkinson's disease (PD) is characterized by progressive neurodegeneration of dopaminergic neurons in the s |
| replication_status | replicated |
| methodology_notes | Phase 1 (Days 1-3): Prepare AAV vectors - AAV2, AAV5, AAV9, and AAV-PHP.eB serotypes carrying identical LRRK2 shRNA constructs under U6 promoter with GFP reporter (1×10^12 vg/ml titer). House 8-week-o |
| primary_outcome | Validate AAV Serotype Comparison for LRRK2 Knockdown in PD Gene Therapy |
| extraction_metadata | {'extraction_confidence': 0.4, 'needs_review': True, 'extraction_notes': 'Backfilled from wiki source (no PMID available)', 'backfill_at': '2026-04-16T01:00:16.900610'} |
🌍 Provenance Graph
9 nodes, 30 edges
derives from (16)
...and 11 more
Linked Artifacts (1390)